Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, ...

Gibson, Dunn & Crutcher has filed multiple suits on behalf or organizations that provide legal services to immigrants, and ...

Now such calls to make clinical trial data transparent – along with openly accessible protocols, papers, and summary results – are really burgeoning, and it’s easy to lose the plot.

Patients with psoriasis, psoriatic arthritis, and axial spondylarthritis using ixekizumab have a low incidence rate of cerebro-cardiovascular events.

A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.